Primary, Secondary Implant Equal for Fibula Free Tissue Transfer

Share this content:
Primary, Secondary Implant Equal for Fibula Free Tissue Transfer
Primary, Secondary Implant Equal for Fibula Free Tissue Transfer

TUESDAY, May 8, 2018 (HealthDay News) -- For patients with a fibula free tissue transfer (FFTT) for osteoradionecrosis (ORN) and osteonecrosis (ON) of the mandible, the rate of complications is similar for patients undergoing primary and secondary dental implantation, according to a study published online May 3 in JAMA Facial Plastic Surgery.

Deanna C. Menapace, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues conducted a retrospective review of 23 patients undergoing primary implantation (12 patients) or secondary implantation (11 patients) after FFTT for ORN and ON.

The researchers found that a mean of 5.2 implants were performed per patient, for a total of 121 implants. In the primary implantation group, there was one complete flap failure. Timing of implantation had no effect on flap or implant complications. In the primary and secondary implantation groups, the implant survival rate was 95 and 98 percent, respectively. The time from FFTT to abutment placement was significantly shorter after primary implantation (19.6 versus 61.0 weeks; P < 0.001). There was no statistically significant improvement in speech and oral competence in the primary implantation group. The fixed unit (U) costs for primary and secondary implantation were 1.0 and 1.24 U, respectively.

"Although dental implantation was safe and effective in both groups, the decreased time to use and the decreased overall cost should prompt surgeons to consider primary implantation after FFTT for ORN and ON," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »